GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (STU:YP2A) » Definitions » Cash Flow for Dividends

BioLine Rx (STU:YP2A) Cash Flow for Dividends : €0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is BioLine Rx Cash Flow for Dividends?

BioLine Rx's cash flow for dividends for the three months ended in Dec. 2023 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

BioLine Rx Cash Flow for Dividends Historical Data

The historical data trend for BioLine Rx's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Cash Flow for Dividends Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioLine Rx Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (STU:YP2A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (STU:YP2A) » Definitions » Cash Flow for Dividends
Comparable Companies
XTAE:CGEN XTAE:SLGN XTAE:BONS XTAE:PPBT XTAE:GFC-M XTAE:EVGN XTAE:DNA XTAE:CBI XTAE:MTLF XTAE:CANF OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BLRX:USA BLRX:Israel
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
Website
https://www.biolinerx.com
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (STU:YP2A) Headlines

No Headlines